Medical Health & Life Science Research News

Immunoassay market worth 27.15 billion USD by 2023 according to new research report

Medical Market Research

According to a new market research report "Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test), Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases, Oncology, Cardiology), End User (Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.

- Advertising -

Browse 293 market data Tables and 50 Figures spread through 344 Pages and in-depth TOC on "Immunoassay Market"

www.marketsandmarkets.com/Market-R…m_campaign=PaidPR

The increasing incidence of chronic and infectious diseases, technological advancements in immunoassay instruments and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical industries are some the major factors driving the growth of this market.

By product and service, the reagents and kits segment commanded the largest share of the market in 2017 

On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services. In 2017, the reagents and kits segment accounted for the largest share of the Immunoassays Market.

The large share of this segment can primarily be attributed to the requirement of the repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.

- Advertising -

The chemiluminescence immunoassays (CLIAs) segment led the Immunoassays Market in 2017 

By platform, this market is classified into CLIAs, radioimmunoassay (RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the largest share of the Immunoassays Market in 2017.

The large share of this segment can primarily be attributed to the low cost and high sensitivity of CLIA-based tests.

Report: www.marketsandmarkets.com/pdfdownl…m_campaign=PaidPR

By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017 

On the basis of technology, the Immunoassays Market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment accounted for the largest share of the Immunoassays Market in 2017.

The large share of this segment can primarily be attributed to the increasing use of immunoassay tests in cancer, infectious diseases, and therapeutic drug level monitoring.

North America held the largest share of the market in 2017 

Based on region, the Immunoassay Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2017.

The large share of this regional segment is attributed to the increasing incidence of chronic diseases and improved healthcare infrastructure.

Key players in the Immunoassays Market include Roche (Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy), QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel Corporation (US), Bio-Techne Corporation (US), and Mindray (China).

Know more about the Immunoassay Market: 

www.marketsandmarkets.com/Market-R…m_campaign=PaidPR

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
This email address is being protected from spambots. You need JavaScript enabled to view it.